- Home
- CROX vs RYTM Comparison
CROX vs RYTM Comparison
Compare CROX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CROX
- RYTM
- Stock Information
- Founded
- CROX 1999
- RYTM 2008
- Country
- CROX United States
- RYTM United States
- Employees
- CROX N/A
- RYTM N/A
- Industry
- CROX Shoe Manufacturing
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- CROX Consumer Discretionary
- RYTM Health Care
- Exchange
- CROX Nasdaq
- RYTM Nasdaq
- Market Cap
- CROX 5.6B
- RYTM 6.4B
- IPO Year
- CROX 2006
- RYTM 2017
- Fundamental
- Price
- CROX $78.99
- RYTM $95.52
- Analyst Decision
- CROX Buy
- RYTM Strong Buy
- Analyst Count
- CROX 12
- RYTM 13
- Target Price
- CROX $105.18
- RYTM $101.92
- AVG Volume (30 Days)
- CROX 1.7M
- RYTM 564.2K
- Earning Date
- CROX 10-28-2025
- RYTM 11-04-2025
- Dividend Yield
- CROX N/A
- RYTM N/A
- EPS Growth
- CROX N/A
- RYTM N/A
- EPS
- CROX 4.12
- RYTM N/A
- Revenue
- CROX $4,138,679,000.00
- RYTM $156,287,000.00
- Revenue This Year
- CROX N/A
- RYTM $44.69
- Revenue Next Year
- CROX $0.86
- RYTM $63.53
- P/E Ratio
- CROX $19.01
- RYTM N/A
- Revenue Growth
- CROX 2.04
- RYTM 53.55
- 52 Week Low
- CROX $73.76
- RYTM $45.91
- 52 Week High
- CROX $151.13
- RYTM $106.52
- Technical
- Relative Strength Index (RSI)
- CROX 37.20
- RYTM 45.59
- Support Level
- CROX $75.74
- RYTM $94.39
- Resistance Level
- CROX $90.06
- RYTM $102.46
- Average True Range (ATR)
- CROX 3.24
- RYTM 3.17
- MACD
- CROX -0.42
- RYTM -1.49
- Stochastic Oscillator
- CROX 20.45
- RYTM 9.27
About CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company are the United States and other Countries.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.